Clinical trial
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC…
NCT01480180 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT01480180 |
|---|---|
| Title | Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A |
| Official title | A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A |
| Acronym | pathfinder™2 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia A |
| Intervention type | Drug |
| Interventions | turoctocog alfa pegol |
| Enrollment | 186 |
| Start date | Jan 30, 2012 |
| Primary completion | Dec 10, 2018 |
| Completion | Dec 10, 2018 |
| First posted | Nov 28, 2011 |
| Last update posted | Nov 23, 2020 |
| Countries | Australia, Brazil, Bulgaria, Croatia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Malaysia and 12 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: